1. Strengths and Challenges of Secretory Ribonucleases as AntiTumor Agents
   Jessica Castro et al, 2021, Pharmaceutics CrossRef
2. Phase II Trial of a Single Weekly Intravenous Dose of Ranpirnase in Patients With Unresectable Malignant Mesothelioma
   Stanislaw M. Mikulski et al, 2002, Journal of Clinical Oncology CrossRef
3. Updates in the Development of ImmunoRNases for the Selective Killing of Tumor Cells
   Sandra Jordaan et al, 2018, Biomedicines CrossRef
4. A Humanized Anti-CD22-Onconase Antibody-Drug Conjugate Mediates Highly Potent Destruction of Targeted Tumor Cells
   Tobias Weber et al, 2015, Journal of Immunology Research CrossRef
5. Role of the Ribonuclease ONCONASE in miRNA Biogenesis and tRNA Processing: Focus on Cancer and Viral Infections
   Marta Menegazzi et al, 2022, International Journal of Molecular Sciences CrossRef
6. Effective therapy of human lymphoma xenografts with a novel recombinant ribonuclease/anti-CD74 humanized IgG4 antibody immunotoxin
   Chien-Hsing Chang et al, 2005, Blood CrossRef